Latest News about ARGX
Recent news which mentions ARGX
Immunovant Could Potentially Be An M&A Target, Writes Analyst
February 15, 2023
From Benzinga
From Benzinga
Alphabet To $115? Here Are 10 Other Price Target Changes For Thursday
December 22, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Thursday
December 01, 2022
From Benzinga
Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position
November 30, 2022
From Benzinga
Argenx's Flagship Neuromuscular Treatment For Subcutaneous Injection Goes Under Priority FDA Review
November 22, 2022
From Benzinga
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022
October 12, 2022
From Benzinga
Immunovant's New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say
September 29, 2022
From Benzinga
Argenx Seeks FDA Nod For Its Flagship Neuromuscular Treatment Formulated For Subcutaneous Injection
September 21, 2022
From Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
August 11, 2022
From Benzinga
From Benzinga
Argenx's Vyvgart To 'Achieve Blockbuster Status,' This Analyst Says With 6% Price Target Hike
July 29, 2022
Tickers
ARGX
From Benzinga
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.